

Public Health Act 1997

DIRECTION UNDER SECTION 16

(Testing of workers at quarantine sites – No. 4)

I, MARK VEITCH, the Director of Public Health, in pursuance of section 16 of the *Public Health Act 1997* ("the Act"), in order to manage the threat to public health posed by the notifiable disease known as COVID-19 ("the disease"), direct that –

- (a) this direction applies to a person if the person was present on a quarantine site on or after the commencement of this direction; and
- (b) paragraph (a) does not apply to a person who has been present on the quarantine site if –
 - (i) the person –
 - (A) is only present on the site for the purposes of delivering goods to, or collecting goods from, the site or providing necessary cleaning or sanitation services in respect of the site; and
 - (B) while present on the site, does not have contact with a person who is in isolation or quarantine at the site; and
 - (C) is only present on the site for a total period of not more than 30 minutes in a 24-hour period; or
 - (ii) the person is present on the site to isolate, or quarantine, in respect of the disease; and
- (c) a person to whom this direction applies must, while this direction so applies to the person, undergo a saliva screening test on each day he or she is present on the relevant quarantine site for the person unless –
 - (i) the person has undergone a saliva screening test, or a nasal swab test, under this direction within the immediately preceding 12-hour period; or
 - (ii) on that day, there are no persons present on the site that are in isolation or quarantine in respect of the disease; or

- (iii) the person is to undergo a nasal swab test on that day in accordance with paragraph (d); and
- (d) subject to paragraph (e), a person to whom this direction applies must, while this direction so applies to the person, undergo a nasal swab test –
 - (i) within the test period after the day on which the person was present on the relevant quarantine site for the person; and
 - (ii) within the test period after the day on which the person last underwent a nasal swab test; and
- (e) if, within the 14-day period immediately before the last day of the test period for a person to whom this direction applies, there were no persons in isolation or quarantine in respect of the disease present on each relevant quarantine site for the person, the person to whom this direction applies is not required to undergo a nasal swab test in accordance with paragraph (d); and
- (f) this direction ceases to apply to a person if –
 - (i) the person has not been present on a quarantine site for at least a 14-day period; and
 - (ii) the person has undergone a nasal swab test for the disease in accordance with paragraph (d) at least 12 days after he or she was last present on such a site; and
- (g) a person to whom this direction applies, or to whom this direction has applied, must provide, on the request of the Director of Public Health or his or her delegate, evidence to the satisfaction of the Director of Public Health, or his or her delegate, that the person has complied with this direction while it applied to the person; and
- (h) as a result of a test for the disease undertaken under this direction by a person to whom this direction applies, the Director of Public Health, or his or her delegate, may require the person to take the action that the Director

of Public Health or his or her delegate considers appropriate in the circumstances and is specified in the requirement; and

- (i) the Director of Public Health, or his or her delegate, may exempt a person, or a specified class of persons, from all or part of this direction subject to such conditions as the Director of Public Health or his or her delegate considers appropriate in the circumstances; and
- (j) in this direction –
 - (i) **nasal swab test** means a nucleic acid test for the genetic material of SARS-CoV-2, that is –
 - (A) conducted on a swab taken from a nostril of a person; and
 - (B) conducted by a laboratory with the relevant accreditation, for nucleic acid testing, by the National Association of Testing Authorities; and
 - (ii) **premises** has the same meaning as in the Act; and
 - (iii) **quarantine site** means the following premises:
 - (A) the premises situated at 393 Argyle St, North Hobart that is being operated under the name “Rydges Hobart”;
 - (B) the premises situated at 156 Bathurst Street, Hobart that is being operated under the name “Best Western Hobart”;
 - (C) the premises situated at 40 Brooker Highway, Hobart that is being operated under the name “UTAS Fountainside Accommodation”;
 - (D) the premises situated at 1 Holyman Avenue, Cambridge that is being operated under the name “Travelodge Hotel Hobart Airport”;
 - (E) the premises situated at 167 Macquarie Street, Hobart that is being operated under the name “Travelodge Hotel Hobart”;
 - (F) the premises situated at 173 Macquarie Street, Hobart that is being operated under the name “Ibis Styles”;
 - (G) the premises situated at 140 North Fenton Street, Devonport that is being operated under the name “Sunrise Motel”; and

- (H) the premises situated at 28 Seaport Boulevard that is being operated under the name “Peppers Seaport Launceston”; and
 - (I) the premises situated at 4 Thomas Street, Devonport that is being operated under the name “Edgewater Hotel”;
 - (J) such part of the premises situated at Country Club Avenue, Prospect Vale, and being operated under the name “Country Club Tasmania”, that is specified by the Director of Public Health, or his or her delegate, as a quarantine site for the purposes of this direction;
 - (K) such part of the premises situated at 425 Waterhouse Road, Bridport, and being operated under the name “Barnbougale Dunes”, that is specified by the Director of Public Health, or his or her delegate, as a quarantine site for the purposes of this direction; and
- (iv) **relevant quarantine site**, in relation to a person, means a quarantine site that resulted, under paragraph (a), in this direction applying to the person; and
 - (v) **saliva screening test** means a nucleic acid test for the genetic material of SARS-CoV-2, that is –
 - (A) conducted on a sample of saliva taken from a person; and
 - (B) conducted by a laboratory that is approved by the Director of Public Health, or his or her delegate, for such a test; and
 - (vi) **test for the disease** means a saliva screening test or a nasal swab test; and
 - (vii) **test period** means a period no less than 5 days, and no greater than 8 days, calculated from, and including, the day from which the test period is to be calculated; and

(k) the direction, given by me on 2 September 2021 and entitled "*Testing of workers at quarantine sites – No. 3*", is revoked.

Dated: 16 September 2021

Signed: 

Director of Public Health